In the phase III PALLAS trial, the addition of 2 years of palbociclib to adjuvant endocrine therapy (ET) did not improve short-term invasive disease-free survival (iDFS) compared with ET alone in high-risk early-stage hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. In this article, we report 5-year efficacy outcomes, including updated iDFS and overall survival (OS).
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)
Annals of Oncology | | E.L. Mayer, D. Hlauschek, M. Gnant, P.J. O'Brien, M. Bellet-Ezquerra, M.P. Goetz, M. Ruiz-Borrego, A. Chan, K. Clifton, D. Egle, D. Lake, P. Cabrera, T. Mamounas, G. Pristauz-Telsnigg, Z. Dayao, M. Gil Gil, D. Cameron, T. Traina, P.G. Morris, D. Sabanathan, G. Rinnerthaler, J. Meisel, A. Prat, A.C. Wolff, L.-M. Tseng, C. Isaacs, C.F. Singer, G. Rubovszky, T. Foukakis, J. Jassem, E.P. Winer, M. Vetter, J. Federmann, O. Metzger, C. Schurmans, E. Gauthier, D.R. Lu, C. Fesl, A. Dueck, A. DeMichele
Topics: breast-cancer, blood-cancer, clinical-trials